deaths (OS)progression or deaths (PFS)RFS/DFS

mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - all population

versus Standard of Care (SoC)
durvalumab plus tremelimumab vs. Standard of Care (SoC) 1 -511 [-1112; 90] /10000
278/372 vs. 297/372
--
nivolumab plus ipilimumab plus SoC vs. Standard of Care (SoC) 1 -1126 [-1852; -399] /10000
156/361 vs. 195/358
-529 [-1215; 158] /10000
232/361 vs. 249/358
-